<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Approach to the patient with facial erythema</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Approach to the patient with facial erythema</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Approach to the patient with facial erythema</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey Callen, MD, FACP, FAAD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Erik Stratman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 24, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3150854130"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Facial erythema (facial redness), a clinical finding most noticeable in individuals with lightly pigmented skin, occurs as a result of cutaneous blood vessel dilation and increased blood flow to the skin. Although transient facial erythema is often observed as a normal, neurologically mediated response to strong emotion, exercise, or heat exposure, inflammation and a variety of medical conditions can lead to longer-lasting and symptomatic or cosmetically distressing facial erythema.</p><p>Examples of disorders that may present with diffuse or localized facial erythema and the evaluation of patients with this clinical finding will be reviewed here. More detailed information on flushing and many of the other disorders associated with facial erythema is available separately. (See  <a class="medical medical_review" href="/d/html/2782.html" rel="external">"Approach to flushing in adults"</a> and <a class="local">'Etiology'</a> below.)</p><p class="headingAnchor" id="H72796935"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>A variety of factors, including primary skin diseases, external insults, and systemic illness may cause facial redness. Knowledge of the distinctive characteristics of these disorders is helpful for diagnosis.</p><p class="headingAnchor" id="H72796980"><span class="h2">Primary inflammatory skin diseases</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rosacea </strong>–<strong> </strong>Centrofacial erythema and telangiectasias are common features of rosacea  (<a class="graphic graphic_picture graphicRef77020 graphicRef131214 graphicRef56083" href="/d/graphic/77020.html" rel="external">picture 1A-C</a>) [<a href="#rid1">1-3</a>]. Affected patients also often exhibit flushing and sensitivity of facial skin. The patient history and physical findings are usually sufficient for the diagnosis of this disorder. Other rosacea subtypes may also demonstrate these clinical features. (See  <a class="medical medical_review" href="/d/html/13621.html" rel="external">"Rosacea: Pathogenesis, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Perioral dermatitis </strong>– Perioral dermatitis (also known as periorificial dermatitis) presents with multiple small, erythematous, inflammatory papules clustered around the mouth, nose, or eyes  (<a class="graphic graphic_picture graphicRef73779" href="/d/graphic/73779.html" rel="external">picture 2</a>). Fine scale is also often present, but the rash is characteristically more red and bumpy than red and scaly. In patients with perioral lesions, the skin immediately adjacent to the vermillion border of the lip is classically spared. Perioral dermatitis most frequently affects young females; occasionally, the disorder occurs in children. (See  <a class="medical medical_review" href="/d/html/13622.html" rel="external">"Perioral (periorificial) dermatitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Seborrheic dermatitis </strong>– Erythema accompanied by greasy, yellow-white scale is a characteristic feature of seborrheic dermatitis in adults  (<a class="graphic graphic_picture graphicRef126095" href="/d/graphic/126095.html" rel="external">picture 3</a>). In patients with dark skin, the scale may have a gray or brown hue  (<a class="graphic graphic_picture graphicRef114635" href="/d/graphic/114635.html" rel="external">picture 4</a>). Involvement of the face typically manifests in the nasolabial folds, eyebrows, glabella, and lateral nasal areas  (<a class="graphic graphic_picture graphicRef56410 graphicRef59104" href="/d/graphic/56410.html" rel="external">picture 5A-B</a>). Other potential sites of involvement include the scalp, ears, chest, axillae, and groin. The diagnosis of seborrheic dermatitis is usually made based upon the clinical findings [<a href="#rid4">4,5</a>]. (See  <a class="medical medical_review" href="/d/html/13669.html" rel="external">"Seborrheic dermatitis in adolescents and adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atopic dermatitis </strong>– Facial involvement of atopic dermatitis is common in infants  (<a class="graphic graphic_picture graphicRef77386 graphicRef77457 graphicRef56461" href="/d/graphic/77386.html" rel="external">picture 6A-C</a>) but may also occur in older children and adults  (<a class="graphic graphic_picture graphicRef75681 graphicRef56815" href="/d/graphic/75681.html" rel="external">picture 7A-B</a>). Intensely pruritic, erythematous patches or plaques with accompanying scale, exudate, excoriations, or lichenification are often seen. The presence of a chronic, very pruritic, dermatitic skin disorder with lichenification in a typical distribution (eg, flexures in adults, cheeks in infants) suggests the possibility of atopic dermatitis [<a href="#rid6">6</a>]. Patients may also exhibit an extra skin fold beneath the bilateral lower eyelids that is known as a Dennie-Morgan fold  (<a class="graphic graphic_picture graphicRef62145" href="/d/graphic/62145.html" rel="external">picture 8</a>). An uncommon variant is photosensitive atopic dermatitis, which occurs predominantly in atopic skin exposed to ultraviolet light [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/d/html/1729.html" rel="external">"Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Psoriasis </strong>– The clinical findings in facial psoriasis may be more subtle than the classic thick plaques with silver scale that are typical of lesions in other body areas  (<a class="graphic graphic_picture graphicRef79191 graphicRef68576" href="/d/graphic/79191.html" rel="external">picture 9A-B</a>). In some patients, lesions closely resemble the erythematous patches and finer scale of seborrheic dermatitis. The detection of lesions consistent with the classic presentation of psoriasis elsewhere on the body is helpful for diagnosis. (See  <a class="medical medical_review" href="/d/html/5664.html" rel="external">"Psoriasis: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H72796988"><span class="h2">Disorders due to external insults</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Irritant contact dermatitis </strong>– Contact with skin care products, cosmetics, or other substances that contain irritants may result in facial eruptions with features of eczematous dermatitis. The dermatitis may be diffuse or localized depending on the sites of contact. The facial folds and the delicate skin of the eyelids are particularly susceptible to more severe involvement. (See  <a class="medical medical_review" href="/d/html/120320.html" rel="external">"Eyelid dermatitis (eczema)"</a>.)</p><p></p><p class="bulletIndent1">Unlike allergic contact dermatitis, which is typically associated with intense pruritus, patients with irritant contact dermatitis tend to complain of burning or prickling sensations [<a href="#rid8">8</a>]. The patient history is critical for identifying this diagnosis. (See  <a class="medical medical_review" href="/d/html/13661.html" rel="external">"Irritant contact dermatitis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Allergic contact dermatitis </strong>– Delayed hypersensitivity reactions to external substances that contact the skin can cause acute, intense inflammatory reactions characterized by bright erythema, scale, and exudate  (<a class="graphic graphic_picture graphicRef67215 graphicRef82705" href="/d/graphic/67215.html" rel="external">picture 10A-B</a>) [<a href="#rid8">8</a>]. Other times, the dermatitis is only mildly inflamed and chronic. Patch testing can be useful for identifying the causative antigenic substance. (See  <a class="medical medical_review" href="/d/html/13655.html" rel="external">"Clinical features and diagnosis of allergic contact dermatitis"</a> and  <a class="medical medical_review" href="/d/html/16691.html" rel="external">"Patch testing"</a>.)</p><p></p><p class="headingAnchor" id="H72796996"><span class="h2">Photosensitive disorders</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sunburn </strong>– The appearance of confluent, erythematous patches following sun exposure is a classic feature of sunburn  (<a class="graphic graphic_picture graphicRef59991" href="/d/graphic/59991.html" rel="external">picture 11</a>). Pruritus or pain may also be present. In severe cases, edema and blistering can occur. Desquamation commonly occurs during healing. (See  <a class="medical medical_review" href="/d/html/6624.html" rel="external">"Sunburn"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Polymorphous light eruption (PMLE) </strong>– Often colloquially referred to as sun poisoning or sun allergy, PMLE may present with a wide variety of clinical manifestations [<a href="#rid9">9,10</a>]. Erythematous patches, papules, vesicles, or plaques may occur within hours to days after sun exposure  (<a class="graphic graphic_picture graphicRef51455" href="/d/graphic/51455.html" rel="external">picture 12</a>). PMLE is particularly likely to occur in early spring, as patient tolerance to sunlight tends to rise with increasing exposure. (See  <a class="medical medical_review" href="/d/html/6623.html" rel="external">"Polymorphous light eruption"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Phototoxic and photoallergic eruptions </strong>– Phototoxic eruptions are sunburn-like reactions induced by the ingestion or application of photosensitizing substances  (<a class="graphic graphic_picture graphicRef69140" href="/d/graphic/69140.html" rel="external">picture 13</a>) [<a href="#rid11">11-14</a>]. The photosensitizing agent decreases the amount of ultraviolet light exposure required to elicit this reaction. Severe eruptions with blistering and edema may occur. (See  <a class="medical medical_review" href="/d/html/6622.html" rel="external">"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment", section on 'Phototoxicity'</a>.)</p><p></p><p class="bulletIndent1">Photoallergic reactions are characterized by pruritic, eczematous eruptions in sun-exposed areas [<a href="#rid11">11-13</a>]. Topical, rather than ingested, agents are the most frequent causes of photoallergic reactions [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/d/html/6622.html" rel="external">"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment", section on 'Photoallergy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Photodamage </strong>– The formation of numerous telangiectasias and a ruddy complexion secondary to chronic sun exposure is a common cause of facial redness [<a href="#rid16">16</a>]. Sun-protected areas of the face are relatively spared. Patients may have accompanying poikiloderma of Civatte, a disorder characterized by mottled pigmentation and telangiectasias on the lateral neck  (<a class="graphic graphic_picture graphicRef81779" href="/d/graphic/81779.html" rel="external">picture 14</a>). (See  <a class="medical medical_review" href="/d/html/15255.html" rel="external">"Photoaging", section on 'Clinical features'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute cutaneous lupus erythematosus, dermatomyositis, and lupus tumidus erythematosus</strong> [<a href="#rid17">17</a>]. (See <a class="local">'Systemic disorders'</a> below and <a class="local">'Localized inflammatory infiltrates'</a> below.)</p><p></p><p class="headingAnchor" id="H72797004"><span class="h2">Systemic disorders</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lupus erythematosus </strong>– Patients with systemic lupus erythematosus may develop acute cutaneous lupus erythematosus, which often manifests as persistent, violaceous erythema on the malar area of the face  (<a class="graphic graphic_picture graphicRef75781 graphicRef55875" href="/d/graphic/75781.html" rel="external">picture 15A-B</a>) [<a href="#rid18">18,19</a>]. This clinical finding is often referred to as a "butterfly rash." The prominent telangiectasias of rosacea are not a feature of acute cutaneous lupus erythematosus. The presence of signs or symptoms of systemic lupus erythematosus suggests this diagnosis. (See  <a class="medical medical_review" href="/d/html/4666.html" rel="external">"Overview of cutaneous lupus erythematosus", section on 'Acute cutaneous lupus erythematosus'</a> and  <a class="medical medical_review" href="/d/html/6420.html" rel="external">"Childhood-onset systemic lupus erythematosus (SLE): Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/4668.html" rel="external">"Clinical manifestations and diagnosis of systemic lupus erythematosus in adults", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1">Patients with subacute cutaneous lupus erythematosus have a photosensitive form of lupus erythematosus. Erythematous, annular, scaly, psoriasiform plaques usually appear on the trunk, but the face may be involved. The inner edge of annular plaques often shows fine, white, trailing scales. Patients may be otherwise usually "healthy," but some may have arthritis or other systemic features of lupus erythematosus. (See  <a class="medical medical_review" href="/d/html/4666.html" rel="external">"Overview of cutaneous lupus erythematosus", section on 'Subacute cutaneous lupus erythematosus'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dermatomyositis </strong>– A classic sign of dermatomyositis is the "heliotrope eruption," a violaceous and often edematous eruption that occurs on the eyelids and periorbital skin  (<a class="graphic graphic_picture graphicRef56879 graphicRef68649" href="/d/graphic/56879.html" rel="external">picture 16A-B</a>). Patients may or may not have accompanying proximal muscle weakness. The detection of other cutaneous signs of dermatomyositis, such as Gottron papules and periungual telangiectasias, raises suspicion for this diagnosis. In addition, the possibility of an underlying malignancy must be considered in adults with dermatomyositis. (See  <a class="medical medical_review" href="/d/html/5159.html" rel="external">"Clinical manifestations of dermatomyositis and polymyositis in adults"</a> and  <a class="medical medical_review" href="/d/html/6419.html" rel="external">"Juvenile dermatomyositis and other idiopathic inflammatory myopathies: Epidemiology, pathogenesis, and clinical manifestations"</a>.)</p><p></p><p class="headingAnchor" id="H1132364904"><span class="h2">Infectious disorders</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Viral infections </strong>– Erythema infectiosum (fifth disease) is a viral disease caused by parvovirus B19, which most commonly occurs in children [<a href="#rid20">20</a>]. A common feature of this disorder is the appearance of red patches on the cheeks that resemble facial skin after a slap on the face  (<a class="graphic graphic_picture graphicRef52251" href="/d/graphic/52251.html" rel="external">picture 17</a>). Nonspecific constitutional symptoms, such as fever, coryza, headache, or gastrointestinal distress, usually precede the cutaneous findings. A reticulated eruption on the trunk and extremities frequently appears one to two days after the facial lesions. (See  <a class="medical medical_review" href="/d/html/8272.html" rel="external">"Clinical manifestations and diagnosis of parvovirus B19 infection", section on 'Erythema infectiosum'</a>.)</p><p></p><p class="bulletIndent1">Morbilliform or confluent facial redness may also occur as early features of other viral infections, such as measles or rubella; other body sites are typically also involved  (<a class="graphic graphic_picture graphicRef61958 graphicRef73806" href="/d/graphic/61958.html" rel="external">picture 18A-B</a>). (See  <a class="medical medical_review" href="/d/html/3021.html" rel="external">"Measles: Clinical manifestations, diagnosis, treatment, and prevention"</a> and  <a class="medical medical_review" href="/d/html/8301.html" rel="external">"Rubella"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Erysipelas </strong>– Erysipelas is a superficial form of cellulitis that usually results from infection with beta-hemolytic streptococci [<a href="#rid21">21</a>]. Patients typically present with the acute development of an erythematous, warm, edematous, and well-defined plaque  (<a class="graphic graphic_picture graphicRef67112 graphicRef132210" href="/d/graphic/67112.html" rel="external">picture 19A-B</a>). Fever and lymphadenopathy often accompany the cutaneous symptoms. (See  <a class="medical medical_review" href="/d/html/110529.html" rel="external">"Cellulitis and skin abscess: Epidemiology, microbiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H648564566"><span class="h2">Localized inflammatory infiltrates</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lupus tumidus erythematosus </strong>– Also known as tumid lupus erythematosus, lupus tumidus erythematosus is an uncommon disorder that presents with erythematous plaques in sun-exposed areas, such as the face, neck, upper trunk, and upper extremities, and scale is typically absent  (<a class="graphic graphic_picture graphicRef71792" href="/d/graphic/71792.html" rel="external">picture 20</a>) [<a href="#rid22">22,23</a>]. The vast majority of patients do not have associated systemic lupus. The performance of a biopsy assists with diagnosis. (See  <a class="medical medical_review" href="/d/html/4666.html" rel="external">"Overview of cutaneous lupus erythematosus", section on 'Lupus erythematosus tumidus'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Jessner's lymphocytic infiltrate </strong>– This idiopathic disorder most commonly manifests as erythematous, asymptomatic, often annular plaques on the face, neck, or upper trunk  (<a class="graphic graphic_picture graphicRef76268 graphicRef62419" href="/d/graphic/76268.html" rel="external">picture 21A-B</a>) [<a href="#rid24">24,25</a>]. A skin biopsy is useful for diagnosis. Jessner's lymphocytic infiltrate shares clinical and histopathologic features with lupus tumidus erythematous. The relationship between these disorders remains unclear [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Granuloma faciale </strong>–<strong> </strong>Granuloma faciale usually presents as a solitary, red-brown, asymptomatic, round plaque with follicular prominence on the face  (<a class="graphic graphic_picture graphicRef50769" href="/d/graphic/50769.html" rel="external">picture 22</a>) [<a href="#rid26">26</a>]. The histopathologic finding of a normal-appearing thin zone in the papillary dermis (Grenz zone) above a dense inflammatory dermal infiltrate containing eosinophils, lymphocytes, neutrophils, and plasma cells is characteristic of this diagnosis. The disorder is most common in White males [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/d/html/13770.html" rel="external">"Granuloma faciale"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cutaneous B cell pseudolymphomas </strong>– Cutaneous B cell pseudolymphomas occur as a result of antigenic stimulation in the skin leading to lymphocyte proliferation. The specific cause is often unknown, but insect bites and infections, including Lyme disease, have been linked to some cases [<a href="#rid27">27,28</a>]. Patients typically present with a red-brown to violaceous nodule or plaque  (<a class="graphic graphic_picture graphicRef103720" href="/d/graphic/103720.html" rel="external">picture 23</a>). A skin biopsy is necessary for diagnosis. (See  <a class="medical medical_review" href="/d/html/102748.html" rel="external">"Cutaneous B cell pseudolymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tinea faciei </strong>–<strong> </strong>Infections with dermatophytic fungi can mimic other acute and chronic facial skin diseases depending upon the nature of the infecting organism and the intensity of the host's defense reaction. In general, facial fungal infections tend to be unilateral; sharply marginated; occasionally annular, scaling, or weeping; and slowly enlarging plaques  (<a class="graphic graphic_picture graphicRef78234" href="/d/graphic/78234.html" rel="external">picture 24</a>) [<a href="#rid29">29</a>]. Potassium hydroxide examination of scale or culture confirms the clinical diagnosis. If lesions have been treated with a topical corticosteroid, they typically seem to improve as inflammation is reduced (tinea incognito) but recur when treatments are stopped. (See  <a class="medical medical_review" href="/d/html/4030.html" rel="external">"Dermatophyte (tinea) infections", section on 'Tinea faciei'</a>.)</p><p></p><p class="headingAnchor" id="H2842730960"><span class="h2">Other</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Flushing </strong>–<strong> </strong>Flushing is characterized by the sudden and transient appearance of facial erythema. The etiology and clinical manifestations of flushing are discussed separately [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/d/html/2782.html" rel="external">"Approach to flushing in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ruddy complexion </strong>– Generalized redness of the skin may occur as a normal feature in some individuals with fair skin (eg, Fitzpatrick skin phototype I or II  (<a class="graphic graphic_table graphicRef60541" href="/d/graphic/60541.html" rel="external">table 1</a>)). Unlike erythematotelangiectatic rosacea, redness is not limited to the central face.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Keratosis pilaris rubra </strong>– Keratosis pilaris rubra faciei is most common in children, adolescents, and young adults with fair complexions. Triangular, erythematous patches are present on the bilateral cheeks  (<a class="graphic graphic_picture graphicRef77270" href="/d/graphic/77270.html" rel="external">picture 25</a>). Follicular keratotic papules are located within the areas of redness, giving the skin a rough texture [<a href="#rid31">31</a>]. Clinical examination is usually sufficient for diagnosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical corticosteroid withdrawal syndrome </strong>–<strong> </strong>Some patients develop a red face from prolonged use of moderate- to high-potency topical corticosteroids on the face. Symptoms of burning or stinging develop within several days after applications are stopped or reduced. Diagnostic difficulties arise from the inability to clearly distinguish the redness from topical corticosteroid withdrawal from the redness due to exacerbation of the underlying dermatosis. Features suggesting topical corticosteroid withdrawal include the appearance of generalized redness of the face within four days of withdrawal and symptoms of pain, especially burning sensations [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/d/html/5565.html" rel="external">"Topical corticosteroids: Use and adverse effects", section on 'Adverse effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Burning face syndrome (facial erythrodysesthesia)</strong> – Painful or burning sensations are associated with facial erythema due to mild dilation of blood vessels. Some patients have rosacea, while others seem to have a neuropathic pain syndrome [<a href="#rid33">33</a>].</p><p></p><p class="headingAnchor" id="H72796943"><span class="h1">PATIENT ASSESSMENT</span><span class="headingEndMark"> — </span>The first step for narrowing the differential diagnosis of facial erythema is the performance of a thorough patient history and skin examination. The recognition of associated symptoms, exacerbating factors, lesion time course, and subtle clinical features of the affected area are often valuable for diagnosis. In addition, the performance of a full skin examination may yield additional skin findings that suggest an underlying cutaneous or systemic disorder.</p><p>The clinician should consider the following points during the patient evaluation:</p><p class="bulletIndent1"><span class="glyph">●</span>What are the physical characteristics of the eruption?</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diffuse and symmetrical without scale – Ruddy complexion, flushing </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diffuse and symmetrical with scale – Irritant contact dermatitis, airborne allergic contact dermatitis, atopic dermatitis in infants</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Symmetrical, central face or cheeks without scale – Rosacea, erythema infectiosum, keratosis pilaris rubra faciei </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Symmetrical, central face with scale – Seborrheic dermatitis, atopic dermatitis, psoriasis</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Photodistributed – Sunburn; polymorphous light eruption; phototoxic reaction; photoallergic reaction; photodamage; acute, subacute, and discoid cutaneous lupus erythematosus; dermatomyositis; lupus erythematosus tumidus</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Localized plaques or patches – Erysipelas, lupus tumidus erythematosus, cutaneous lymphoid hyperplasia, Jessner's lymphocytic infiltrate, granuloma faciale</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Presence of telangiectasias – Photodamage, rosacea</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Are there associated symptoms?</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prominent pruritus – Allergic contact dermatitis, atopic dermatitis, photoallergic reaction</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Painful or burning sensations – Sunburn, irritant contact dermatitis, phototoxicity, erysipelas, rosacea</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sick patient – Lupus erythematosus, dermatomyositis, systemic infection, drug eruption</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>How long has the eruption been present; how long do symptoms last?</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acute – Allergic contact dermatitis, atopic dermatitis flare, erythema infectiosum and other viral infections, sunburn, phototoxic reaction, photoallergic reaction</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Transient – Flushing</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Has the patient applied any products to the skin that could cause an irritant or allergic reaction?</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Allergic contact dermatitis, irritant contact dermatitis, photoallergic reaction</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Is the eruption exacerbated by sun exposure?</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sunburn, phototoxic reaction, photoallergic reaction, cutaneous lupus erythematosus, dermatomyositis, lupus tumidus erythematosus</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Is the patient ingesting any photosensitizing medications or supplements  (<a class="graphic graphic_table graphicRef62152" href="/d/graphic/62152.html" rel="external">table 2</a>)?</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Phototoxic reaction, occasionally photoallergic reactions</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Are other body sites involved, and in what distribution?</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Psoriasis, atopic dermatitis, seborrheic dermatitis, viral exanthems, drug eruptions, photodermatoses, erythroderma, other disorders</p><p></p><p class="headingAnchor" id="H72796957"><span class="h1">DIAGNOSTIC TESTS</span><span class="headingEndMark"> — </span>The workup of patients with facial redness is dependent upon the disorders suspected as a result of the clinical assessment. Diagnostic tests that can be useful for the evaluation of select patients include:</p><p class="bulletIndent1"><span class="glyph">●</span>Patch testing</p><p class="bulletIndent1"><span class="glyph">●</span>Skin biopsy</p><p class="bulletIndent1"><span class="glyph">●</span>Directed serologic studies (eg, investigative tests for autoimmune disease)</p><p></p><p class="headingAnchor" id="H402943"><span class="h2">Patch testing</span><span class="headingEndMark"> — </span>Patch testing can be useful for identifying the causative allergen in patients with contact dermatitis. The procedure is most appropriate for patients in whom an allergic contact dermatitis is strongly suspected (eg, history of contact with a potential allergen, paroxysmal nature of eruptions, or severe pruritus) or in patients with persistent, pruritic, eczematous facial eruptions without another identifiable cause. (See  <a class="medical medical_review" href="/d/html/16691.html" rel="external">"Patch testing"</a>.)</p><p>The results of patch testing must be interpreted carefully since a positive patch test result does not definitively indicate that a specific allergen is the cause of dermatitis. A thorough patient interview prior to patch testing and reevaluation following the elimination of the identified allergen are essential for confirming the relevance of patch test results.</p><p class="headingAnchor" id="H402950"><span class="h2">Biopsy</span><span class="headingEndMark"> — </span>Skin biopsies are not necessary in most patients with facial erythema, as a thorough clinical history and skin examination often yields the diagnosis. However, in cases in which the diagnosis remains uncertain and the disorders being considered have distinctive histopathologic findings, skin biopsies can be of value. </p><p>Punch biopsies are typically performed for the evaluation of facial dermatoses as they allow for the evaluation of the full thickness of the epidermis and dermis through the removal of a relatively small skin sample. We most commonly perform 3 mm punch biopsies when evaluating inflammatory facial dermatoses. Larger punch biopsies are typically avoided to minimize scarring, and smaller biopsies may increase the risk for inconclusive histopathologic results. (See  <a class="medical medical_review" href="/d/html/5577.html" rel="external">"Skin biopsy techniques", section on 'Punch biopsy'</a>.)</p><p>If multiple sites are acceptable for biopsy, a site that minimizes cosmetic disfigurement should be selected.</p><p class="headingAnchor" id="H404013"><span class="h2">Serology and other tests</span><span class="headingEndMark"> — </span>Serologic studies and other investigative tests may be useful in the diagnostic workup of patients with facial redness related to systemic disorders such as acute cutaneous lupus erythematosus, dermatomyositis, or certain infections. The selection of studies is based upon the clinical suspicion for specific underlying disorders. (See  <a class="medical medical_review" href="/d/html/4668.html" rel="external">"Clinical manifestations and diagnosis of systemic lupus erythematosus in adults"</a> and  <a class="medical medical_review" href="/d/html/6420.html" rel="external">"Childhood-onset systemic lupus erythematosus (SLE): Clinical manifestations and diagnosis", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/6409.html" rel="external">"Juvenile dermatomyositis and other idiopathic inflammatory myopathies: Diagnosis"</a> and  <a class="medical medical_review" href="/d/html/15653.html" rel="external">"Diagnosis and differential diagnosis of dermatomyositis and polymyositis in adults", section on 'Laboratory testing and imaging'</a>.)</p><p class="headingAnchor" id="H769966"><span class="h1">TOPICAL CORTICOSTEROID USE</span><span class="headingEndMark"> — </span>The treatment of facial erythema should be selected based upon the measures appropriate for the specific underlying disorder. For corticosteroid-responsive inflammatory dermatoses, low-potency agents (eg, <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a> 1% or 2.5%) are most frequently employed to minimize risk for the induction of acneiform eruptions and cutaneous atrophy that may lead to telangiectasias and a red hue to the skin  (<a class="graphic graphic_table graphicRef62402" href="/d/graphic/62402.html" rel="external">table 3</a>). </p><p>With the exception of specific disorders in which higher-potency topical corticosteroids are required (eg, discoid lupus erythematosus), the use of medium- or high-potency topical corticosteroids for inflammatory facial dermatoses generally is not recommended. Facial dermatoses requiring treatment with medium- or high-potency topical corticosteroids are best managed by a dermatologist. (See  <a class="medical medical_review" href="/d/html/5565.html" rel="external">"Topical corticosteroids: Use and adverse effects", section on 'Adverse effects'</a>.)</p><p class="headingAnchor" id="H72796966"><span class="h1">INDICATIONS FOR REFERRAL</span><span class="headingEndMark"> — </span>Evaluation by a dermatologist is appropriate for patients with facial redness of unknown cause or that fails to respond as expected to therapy. Facial biopsies and patch testing are best performed by clinicians trained in these procedures. (See <a class="local">'Patch testing'</a> above and <a class="local">'Biopsy'</a> above.)</p><p class="headingAnchor" id="H402961"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Facial redness is a common cutaneous finding that may occur as a normal feature or as a consequence of cutaneous or systemic disorders. Examples of conditions that may lead to facial redness include inflammatory skin disease, photosensitive disorders, autoimmune disorders, vascular reactions, and infections. (See <a class="local">'Etiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The evaluation of the patient with facial redness begins with a thorough patient history and whole body skin examination. Details such as the features of cutaneous lesions, symptoms, duration of the eruption, and exacerbating factors should be assessed. (See <a class="local">'Patient assessment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although the diagnosis of disorders of facial erythema can commonly be made based upon the patient history and clinical examination, patch testing, skin biopsy, or laboratory studies may be beneficial in select patients. Antinuclear antibody testing is not indicated in all patients with facial redness. (See <a class="local">'Diagnostic tests'</a> above.)</p><p></p><p class="headingAnchor" id="H1208228452"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate acknowledge Mark V Dahl, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol 2002; 46:584.</a></li><li><a class="nounderline abstract_t">Saleem MD, Wilkin JK. Evaluating and Optimizing the Diagnosis of Erythematotelangiectatic Rosacea. Dermatol Clin 2018; 36:127.</a></li><li><a class="nounderline abstract_t">Gallo RL, Granstein RD, Kang S, et al. Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol 2018; 78:148.</a></li><li><a class="nounderline abstract_t">Naldi L, Rebora A. Clinical practice. Seborrheic dermatitis. N Engl J Med 2009; 360:387.</a></li><li><a class="nounderline abstract_t">Ramos-E-Silva M, Sampaio AL, Carneiro S. Red face revisited: Endogenous dermatitis in the form of atopic dermatitis and seborrheic dermatitis. Clin Dermatol 2014; 32:109.</a></li><li><a class="nounderline abstract_t">Leung DY, Bieber T. Atopic dermatitis. Lancet 2003; 361:151.</a></li><li><a class="nounderline abstract_t">Ellenbogen E, Wesselmann U, Hofmann SC, Lehmann P. Photosensitive atopic dermatitis--a neglected subset: Clinical, laboratory, histological and photobiological workup. J Eur Acad Dermatol Venereol 2016; 30:270.</a></li><li><a class="nounderline abstract_t">Nosbaum A, Vocanson M, Rozieres A, et al. Allergic and irritant contact dermatitis. Eur J Dermatol 2009; 19:325.</a></li><li><a class="nounderline abstract_t">Hönigsmann H. Polymorphous light eruption. Photodermatol Photoimmunol Photomed 2008; 24:155.</a></li><li><a class="nounderline abstract_t">Guarrera M. Polymorphous Light Eruption. Adv Exp Med Biol 2017; 996:61.</a></li><li><a class="nounderline abstract_t">Millard TP, Hawk JL. Photosensitivity disorders: cause, effect and management. Am J Clin Dermatol 2002; 3:239.</a></li><li><a class="nounderline abstract_t">Zuba EB, Koronowska S, Osmola-Mańkowska A, Jenerowicz D. Drug-induced Photosensitivity. Acta Dermatovenerol Croat 2016; 24:55.</a></li><li><a class="nounderline abstract_t">Choi D, Kannan S, Lim HW. Evaluation of patients with photodermatoses. Dermatol Clin 2014; 32:267.</a></li><li><a class="nounderline abstract_t">Monteiro AF, Rato M, Martins C. Drug-induced photosensitivity: Photoallergic and phototoxic reactions. Clin Dermatol 2016; 34:571.</a></li><li><a class="nounderline abstract_t">González E, González S. Drug photosensitivity, idiopathic photodermatoses, and sunscreens. J Am Acad Dermatol 1996; 35:871.</a></li><li><a class="nounderline abstract_t">Helfrich YR, Maier LE, Cui Y, et al. Clinical, Histologic, and Molecular Analysis of Differences Between Erythematotelangiectatic Rosacea and Telangiectatic Photoaging. JAMA Dermatol 2015; 151:825.</a></li><li><a class="nounderline abstract_t">Kazandjieva J, Tsankov N, Pramatarov K. The red face revisited: connective tissue disorders. Clin Dermatol 2014; 32:153.</a></li><li><a class="nounderline abstract_t">Walling HW, Sontheimer RD. Cutaneous lupus erythematosus: issues in diagnosis and treatment. Am J Clin Dermatol 2009; 10:365.</a></li><li><a class="nounderline abstract_t">Ribero S, Sciascia S, Borradori L, Lipsker D. The Cutaneous Spectrum of Lupus Erythematosus. Clin Rev Allergy Immunol 2017; 53:291.</a></li><li><a class="nounderline abstract_t">Vafaie J, Schwartz RA. Erythema infectiosum. J Cutan Med Surg 2005; 9:159.</a></li><li><a class="nounderline abstract_t">Bonnetblanc JM, Bédane C. Erysipelas: recognition and management. Am J Clin Dermatol 2003; 4:157.</a></li><li><a class="nounderline abstract_t">Choonhakarn C, Poonsriaram A, Chaivoramukul J. Lupus erythematosus tumidus. Int J Dermatol 2004; 43:815.</a></li><li><a class="nounderline abstract_t">Obermoser G, Sontheimer RD, Zelger B. Overview of common, rare and atypical manifestations of cutaneous lupus erythematosus and histopathological correlates. Lupus 2010; 19:1050.</a></li><li><a class="nounderline abstract_t">Poenitz N, Dippel E, Klemke CD, et al. Jessner's lymphocytic infiltration of the skin: a CD8+ polyclonal reactive skin condition. Dermatology 2003; 207:276.</a></li><li><a class="nounderline abstract_t">Rémy-Leroux V, Léonard F, Lambert D, et al. Comparison of histopathologic-clinical characteristics of Jessner's lymphocytic infiltration of the skin and lupus erythematosus tumidus: Multicenter study of 46 cases. J Am Acad Dermatol 2008; 58:217.</a></li><li><a class="nounderline abstract_t">Thiyanaratnam J, Doherty SD, Krishnan B, Hsu S. Granuloma faciale: Case report and review. Dermatol Online J 2009; 15:3.</a></li><li><a class="nounderline abstract_t">Colli C, Leinweber B, Müllegger R, et al. Borrelia burgdorferi-associated lymphocytoma cutis: clinicopathologic, immunophenotypic, and molecular study of 106 cases. J Cutan Pathol 2004; 31:232.</a></li><li><a class="nounderline abstract_t">Mullegger RR. Dermatological manifestations of Lyme borreliosis. Eur J Dermatol 2004; 14:296.</a></li><li><a class="nounderline abstract_t">Welsh O, Vera-Cabrera L. Red face and fungi infection. Clin Dermatol 2014; 32:734.</a></li><li><a class="nounderline abstract_t">İkizoğlu G. Red face revisited: Flushing. Clin Dermatol 2014; 32:800.</a></li><li><a class="nounderline abstract_t">Marqueling AL, Gilliam AE, Prendiville J, et al. Keratosis pilaris rubra: a common but underrecognized condition. Arch Dermatol 2006; 142:1611.</a></li><li><a class="nounderline abstract_t">Hajar T, Leshem YA, Hanifin JM, et al. A systematic review of topical corticosteroid withdrawal ("steroid addiction") in patients with atopic dermatitis and other dermatoses. J Am Acad Dermatol 2015; 72:541.</a></li><li><a class="nounderline abstract_t">Affleck A, Stewart M. Burning red face syndrome: a heterogeneous group of facial erythrodysaesthesias. Clin Exp Dermatol 2016; 41:430.</a></li></ol></div><div id="topicVersionRevision">Topic 13686 Version 17.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11907512" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29499796" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Evaluating and Optimizing the Diagnosis of Erythematotelangiectatic Rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29089180" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19164189" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clinical practice. Seborrheic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24314384" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Red face revisited: Endogenous dermatitis in the form of atopic dermatitis and seborrheic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12531593" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Atopic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26523351" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Photosensitive atopic dermatitis--a neglected subset: Clinical, laboratory, histological and photobiological workup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19447733" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Allergic and irritant contact dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18477138" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Polymorphous light eruption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29124691" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Polymorphous Light Eruption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12010069" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Photosensitivity disorders: cause, effect and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27149132" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Drug-induced Photosensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24891050" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Evaluation of patients with photodermatoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27638435" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Drug-induced photosensitivity: Photoallergic and phototoxic reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8959945" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Drug photosensitivity, idiopathic photodermatoses, and sunscreens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25798811" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Clinical, Histologic, and Molecular Analysis of Differences Between Erythematotelangiectatic Rosacea and Telangiectatic Photoaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24314389" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The red face revisited: connective tissue disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19824738" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Cutaneous lupus erythematosus: issues in diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28752372" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The Cutaneous Spectrum of Lupus Erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16502203" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Erythema infectiosum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12627991" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Erysipelas: recognition and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15533063" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Lupus erythematosus tumidus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20693199" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Overview of common, rare and atypical manifestations of cutaneous lupus erythematosus and histopathological correlates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14571070" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Jessner's lymphocytic infiltration of the skin: a CD8+ polyclonal reactive skin condition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18083273" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Comparison of histopathologic-clinical characteristics of Jessner's lymphocytic infiltration of the skin and lupus erythematosus tumidus: Multicenter study of 46 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20040253" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Granuloma faciale: Case report and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14984575" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Borrelia burgdorferi-associated lymphocytoma cutis: clinicopathologic, immunophenotypic, and molecular study of 106 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15358567" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Dermatological manifestations of Lyme borreliosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25441465" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Red face and fungi infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25441473" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Red face revisited: Flushing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17178988" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Keratosis pilaris rubra: a common but underrecognized condition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25592622" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A systematic review of topical corticosteroid withdrawal ("steroid addiction") in patients with atopic dermatitis and other dermatoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26455507" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Burning red face syndrome: a heterogeneous group of facial erythrodysaesthesias.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
